Neos Therapeutics Inc (NASDAQ:NEOS)’s share price hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $4.75 and last traded at $4.85, with a volume of 13251 shares changing hands. The stock had previously closed at $5.05.

Several equities analysts have recently issued reports on NEOS shares. ValuEngine raised Neos Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, September 18th. Zacks Investment Research raised Neos Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 11th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $20.00 price target on shares of Neos Therapeutics in a research note on Wednesday, August 8th. Finally, Wells Fargo & Co cut their price target on Neos Therapeutics from $14.00 to $11.00 and set a “buy” rating on the stock in a research note on Thursday, August 9th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Neos Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $13.33.

The company has a quick ratio of 0.84, a current ratio of 1.07 and a debt-to-equity ratio of -2.36. The company has a market cap of $148.37 million, a PE ratio of -1.86 and a beta of -0.32.

Neos Therapeutics (NASDAQ:NEOS) last issued its quarterly earnings results on Wednesday, August 8th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.08). Neos Therapeutics had a negative net margin of 164.40% and a negative return on equity of 586.25%. The firm had revenue of $11.36 million for the quarter, compared to analyst estimates of $11.90 million. equities research analysts predict that Neos Therapeutics Inc will post -1.69 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its stake in Neos Therapeutics by 13.9% in the second quarter. BlackRock Inc. now owns 2,091,282 shares of the company’s stock valued at $13,070,000 after buying an additional 255,037 shares during the period. Lyon Street Capital LLC lifted its stake in Neos Therapeutics by 85.8% in the first quarter. Lyon Street Capital LLC now owns 1,455,614 shares of the company’s stock valued at $12,082,000 after buying an additional 672,031 shares during the period. Russell Investments Group Ltd. lifted its stake in Neos Therapeutics by 65.8% in the first quarter. Russell Investments Group Ltd. now owns 829,298 shares of the company’s stock valued at $6,884,000 after buying an additional 329,128 shares during the period. Nexthera Capital LP acquired a new position in Neos Therapeutics in the second quarter valued at about $2,369,000. Finally, Proxima Capital Management LLC lifted its stake in Neos Therapeutics by 34.1% in the second quarter. Proxima Capital Management LLC now owns 295,000 shares of the company’s stock valued at $1,844,000 after buying an additional 75,000 shares during the period. 47.47% of the stock is currently owned by hedge funds and other institutional investors.

Neos Therapeutics Company Profile (NASDAQ:NEOS)

Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.

Recommended Story: How Do Tariffs Affect Trade Balances?

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.